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ABSTRACT
PTPN11 gain-of-function mutation is the most common mutation found in patients 
with juvenile myelomonocytic leukemia and DNMT3A loss occurs in over 20% of acute 
myeloid leukemia patients. We studied the combined effect of both Ptpn11 gain-of-
function mutation (D61Y) and Dnmt3a haploinsufficiency on mouse hematopoiesis, 
the presence of which has been described in both juvenile myelomonocytic leukemia 
and acute myeloid leukemia patients. Double mutant mice rapidly become moribund 
relative to any of the other genotypes, which is associated with enlargement of the 
spleen and an increase in white blood cell counts. An increase in the mature myeloid 
cell compartment as reflected by the presence of Gr1+Mac1+ cells was also observed in 
double mutant mice relative to any other group. Consistent with these observations, 
a significant increase in the absolute number of granulocyte macrophage progenitors 
(GMPs) was seen in double mutant mice. A decrease in the lymphoid compartment 
including both T and B cells was noted in the double mutant mice. Another significant 
difference was the presence of extramedullary erythropoiesis with increased erythroid 
progenitors in the spleens of Dnmt3a+/−;D61Y mice relative to other groups. Taken 
together, our results suggest that the combined haploinsufficiency of Dnmt3a and 
presence of an activated Shp2 changes the composition of multiple hematopoietic 
lineages in mice relative to the individual heterozygosity of these genes.
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INTRODUCTION
Loss of DNA methyltransferase 3A (DNMT3A) 
activity has been shown to lead to hematopoietic stem 
cell differentiation defects and the development of 
myeloid malignancies. DNMT3A is commonly mutated 
in myeloid diseases, with mutations found in over 20% 
of all acute myeloid leukemia (AML) patients [1], in 8% 
of myelodysplastic syndrome (MDS) patients [2], and in 
smaller frequencies in other leukemias. For AML patients, 
60% of those with a DNMT3A mutation are heterozygous 
at Arginine 882 (R882), a dominant negative mutation that 
results in less than 80% protein activity [3]. The remaining 
patients usually demonstrate a compound heterozygous or 
homozygous mutation. 
In contrast to AML, individuals with clonal 
hematopoiesis commonly bear a loss-of-function mutation 
in only one copy of DNMT3A [4]. In this pre-leukemic 
state, almost all DNMT3A mutations are nonsynonymous, 
truncating, or splicing, and mutations in R882 are rare [5]. 
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These otherwise healthy individuals are at an increased 
risk of developing MDS/AML due to acquisition of 
a second driver mutation [6] and tend to have a poor 
overall prognosis [1]. Thus, although DNMT3A protein 
function must be almost completely lost in order to cause 
malignancy [7], heterozygous loss-of-function mutations 
are often found combined with a driver mutation in the 
development of frank leukemia. Furthermore, Dnmt3a 
haploinsufficiency alone with no other lesions is sufficient 
for mice to develop myeloid malignancies when aged to 
18–24 months [8].
Here, we studied the effects of Dnmt3a 
haploinsufficiency combined with Ptpn11D61Y, a gain-of-
function mutation in the protein tyrosine phosphatase 
SHP2, which is the most commonly mutated gene in 
juvenile myelomonocytic leukemia (JMML) and is 
used as a mouse model of myeloproliferative disease 
[9]. Concurrent mutations in both DNMT3A and 
PTPN11, albeit rare, have been reported in AML [10, 
11] and in JMML patients [12]. JMML is an aggressive 
myeloproliferative neoplasm (MPN) of early childhood 
with no effective chemotherapeutic treatment and a poor 
prognosis.
RESULTS
We crossed Ptpn11D61Y/+;Mx1-Cre+ mice [9] 
with Dnmt3a+/− mice [13] to produce Mx1-Cre- 
(WT), Dnmt3a+/−;Ptpn11+/+;Mx1-Cre+ (Dnmt3a+/−), 
Dnmt3a+/+;Ptpn11D61Y/+;Mx1-Cre+ (D61Y), and 
Dnmt3a+/−;Ptpn11D61Y/+;Mx1-Cre+ (Dnmt3a+/−;D61Y) 
mice. Six cohorts of mice, with 1 to 4 mice per genotype, 
were treated with polyI:polyC to knockout one copy of 
Dnmt3a and to knock-in the mutant Ptpn11D61Y allele. 
All mice were followed until the Dnmt3a+/−;D61Y mice 
became moribund and the entire cohort was euthanized for 
analysis, which occurred at an average of 24 weeks after 
polyI:polyC treatment. We found that at the time when the 
Dnmt3a+/−;D61Y mice appeared moribund (thin, hunched, 
increased respiratory rate and effort, abdominal distension, 
ruffled fur, pale extremities), the Mx1-Cre− or single 
mutant mice of the same cohort remained healthy. Upon 
euthanasia, the Dnmt3a+/−;D61Y mice showed obvious 
splenomegaly and the spleen to body weight percentage 
was significantly increased compared to the other three 
genotypes (Figure 1A). In addition to splenomegaly, the 
double mutant mice also showed significantly higher 
peripheral blood WBC counts compared to WT or 
Dnmt3a+/− mice (Figure 1B). 
Flow cytometric analysis of the spleen and peripheral 
blood to assess the frequency of Gr1+Mac1+ myeloid cells 
revealed a significantly higher percentage of these mature 
myeloid cells in the Dnmt3a+/−;D61Y mice compared to 
WT and Dnmt3a+/− mice in the spleen, and compared 
to WT mice in the peripheral blood (Figure 2A–2D). 
In contrast, the myeloid cell frequencies in the single 
mutant mice were not statistically different from WT mice 
except for D61Y mice in the peripheral blood (Figure 2C 
and 2D). The absolute number of Gr1+Mac1+ cells were 
also significantly greater in double mutant mice relative to 
the WT and Dnmt3a+/− mice (Figure 2E). In contrast to the 
increase in myeloid cells, the T and B cells were decreased 
in the spleen and peripheral blood of Dnmt3a+/−;D61Y 
mice relative to other groups (Figure 3A and 3B).
In an effort to explain the increase in mature 
myeloid cells in the double mutant mice, we performed 
flow cytometric analysis on bone marrow cells from 
all four genotypes to assess the number of granulocyte 
Figure 1: Dnmt3a+/−;D61Y mice show splenomegaly and leukocytosis at the time of death. (A) Average spleen to body 
weight ratio of mice at the time of euthanasia; n = 13 for WT, n = 9 for Dnmt3a+/−, n = 10 for D61Y, n = 6 for Dnmt3a+/−;D61Y, *p < 0.0001 
comparing Dnmt3a+/−;D61Y to WT, *p = 0.003 comparing Dnmt3a+/−;D61Y to Dnmt3a+/−, *p = 0.003 comparing Dnmt3a+/−;D61Y to D61Y; 
statistical analyses performed by unpaired, two-tailed, Student’s t-test. (B) Average WBC count in peripheral blood of mice immediately 
prior to euthanasia; n = 8 for WT, n = 7 for Dnmt3a+/−, n = 5 for D61Y, n = 5 for Dnmt3a+/−;D61Y; *p = 0.0157 comparing Dnmt3a+/−;D61Y 
to WT, *p = 0.018 comparing Dnmt3a+/−;D61Y to Dnmt3a+/−; statistical analyses performed by unpaired, two-tailed, Student’s t-test.
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macrophage progenitors (GMPs). As seen in Figure 4, 
Dnmt3a+/−;D61Y mice showed a significant increase 
in the absolute number of GMPs compared to WT and 
Dnmt3a+/− mice. The double mutant mice also had 
significantly more absolute numbers of megakaryocyte 
erythrocyte progenitors (MEPs) compared to WT mice, 
but no significant differences in common myeloid 
progenitors (CMPs) were observed among any of the 
four groups (Figure 4). The double mutant mice also 
showed signs of anemia, with significant decreases in 
peripheral red blood cell counts, hemoglobin levels, 
as well as hematocrits relative to WT mice (Figure 
5A–5C). Consistent with these observations, within the 
erythroid lineage, the CD36+CD71+ erythroid progenitors 
(EPs) were significantly increased in the spleens of 
the Dnmt3a+/−;D61Y mice, suggesting compensatory 
erythropoiesis (Figure 5D and 5E). Although EP frequency 
was not increased in the Dnmt3a+/−;D61Y bone marrow 
compartment (data not shown), the increased splenic 
erythropoiesis may explain the increased bone marrow 
MEP numbers.
DISCUSSION
AML patients often have complete loss of DNMT3A 
enzyme activity, but its role when only partially inhibited 
and in combination with a second driver mutation of 
leukemia is not known. Here we show that mice with 
heterozygous loss of Dnmt3a combined with a gain-
of-function Shp2 mutation, D61Y, develop more rapid 
disease progression and earlier mortality. Mice expressing 
Shp2D61Y do not usually succumb to leukemia until 45 
weeks after induction of expression [9] and mice with 
Dnmt3a haploinsufficiency do not develop disease until 
approximately 80 weeks [8]. We found that mice with the 
two mutations together become moribund much earlier 
at 24 weeks, indicating that they cooperate to promote 
myeloid leukemia progression and to shorten survival. 
The most marked phenotypic changes we observed 
in the Dnmt3a+/−;D61Y mice were splenomegaly, mature 
myeloid cell expansion in the periphery as well as 
increased GMPs in the bone marrow. These mice also 
exhibited signs of anemia, perhaps due to defects in 
Figure 2: Dnmt3a+/−;D61Y mice have increased myeloid cells in the periphery at the time of death. (A) Spleen average 
percentage of myeloid cells (Gr1+Mac1+) gated on live events and (B) representative flow diagrams; n = 10 for WT, n = 7 for Dnmt3a+/−, 
n = 9 for D61Y, n = 5 for Dnmt3a+/−;D61Y, *p = 0.0095 comparing Dnmt3a+/−;D61Y to WT, *p = 0.0177 comparing Dnmt3a+/−;D61Y to 
Dnmt3a+/−; statistical analyses performed by unpaired, two-tailed, Student’s t-test. (C) Peripheral blood average percentage of myeloid 
cells (Gr1+Mac1+) gated on live events and (D) representative flow diagrams; n = 12 for WT, n = 9 for Dnmt3a+/−, n = 9 for D61Y, 
n = 5 for Dnmt3a+/−;D61Y, *p = 0.0025 comparing Dnmt3a+/−;D61Y to WT, *p = 0.0009 comparing D61Y to WT; statistical analyses 
performed by unpaired, two-tailed, Student’s t-test. (E) Peripheral blood average absolute number of myeloid cells (Gr1+Mac1+) calculated 
by multiplying percentage and WBC count; n = 12 for WT, n = 9 for Dnmt3a+/−, n = 9 for D61Y, n = 5 for Dnmt3a+/−;D61Y, *p = 0.0002 
comparing Dnmt3a+/−;D61Y to WT, *p = 0.0034 comparing Dnmt3a+/−;D61Y to Dnmt3a+/−, *p = 0.0003 comparing D61Y to WT, *p = 
0.0159 comparing D61Y to Dnmt3a+/−; statistical analyses performed by unpaired, two-tailed, Student’s t-test.
Oncotarget6058www.impactjournals.com/oncotarget
erythrocyte cell maturation in the bone marrow. In support 
of this notion, MEPs in the bone marrow of compound 
mutant mice were increased and there were more erythroid 
progenitors present in the spleen, which most likely 
contributed to the splenomegaly in these mice.
The disease course of JMML also exhibits 
pronounced splenomegaly, sometimes even in the absence 
of highly elevated WBC count. It has been previously 
reported that mice with Dnmt3a−/− combined with KrasG12D/+ 
mutation, another common mutation found in JMML 
patients, developed stress erythropoiesis in the spleen 
[14]. Perhaps one reason JMML patients develop extreme 
splenomegaly is compensatory splenic erythropoiesis, as 
observed in the Dnmt3a+/−;D61Y mice in this study. 
Figure 4: Dnmt3a+/−;D61Y mice have increased GMPs and MEPs in the bone marrow at the time of death. (A) Absolute 
numbers of granulocyte monocyte progenitors (GMPs), common myeloid progenitors (CMPs), and megakaryocyte erythrocyte progenitors 
(MEPs) in bone marrow, gated on lineage−cKit+Sca1− events and (B) representative flow diagrams; n = 10 for WT, n = 6 for Dnmt3a+/−, 
n = 6 for D61Y, n = 4 for Dnmt3a+/−;D61Y, *p = 0.0159 comparing Dnmt3a+/−;D61Y GMPs to WT GMPs, *p = 0.0445 comparing 
Dnmt3a+/−;D61Y GMPs to Dnmt3a+/− GMPs, *p = 0.0186 comparing Dnmt3a+/−;D61Y MEPs to WT MEPs; statistical analyses performed 
by unpaired, two-tailed, Student’s t-test.
Figure 3: Dnmt3a+/−;D61Y mice have decreased B and T cells in the periphery at the time of death. (A) Spleen average 
percentage of B cells (CD19+ or B220+) and T cells (CD4+ or CD8+) gated on live events; n = 13 for WT, n = 9 for Dnmt3a+/−, n = 9 for 
D61Y, n = 6 for Dnmt3a+/−;D61Y, *p = 0.0386 comparing Dnmt3a+/−;D61Y to WT B cells, *p = 0.0013 comparing Dnmt3a+/−;D61Y to WT 
T cells; statistical analyses performed by unpaired, two-tailed, Student’s t-test. (B) Peripheral blood average percentage of B cells (CD19+ 
or B220+) and T cells (CD4+ or CD8+) gated on live events; n = 12 for WT, n = 9 for Dnmt3a+/−, n = 9 for D61Y, n = 5 for Dnmt3a+/−;D61Y, 
*p = 0.0071 comparing Dnmt3a+/−;D61Y to WT T cells; statistical analyses performed by unpaired, two-tailed, Student’s t-test.
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Because DNMT3A and PTPN11 mutations are 
found in combination in AML and JMML patients, our 
double mutant mice provide a novel clinically relevant 
model for developing and evaluating therapies for 
myeloid leukemia. In AML, the presence of a DNMT3A 
mutation led to significantly shortened overall survival 
[1]. For JMML, a disease with poor prognosis, there is 
currently no established decision-making process for 
determining which patients would be candidates for 
experimental therapies. However, it is known that the 
number of mutations present at diagnosis is strongly 
correlated with survival when comparing patients who 
have 0–1 mutations to those with 2 or more mutations 
[12]. Further work must be done to find the importance 
of having specifically the DNMT3A and PTPN11 genes 
mutated together, but these are two commonly mutated 
genes in myeloid leukemia that we have now shown leads 
to accelerated disease. 
The mechanism of how Dnmt3a loss cooperates 
with driver mutations to accelerate disease progression 
is still unknown, but our Dnmt3a+/−;D61Y mouse model 
will be useful to explore this question. We speculate that 
the changes in methylation caused by reduced DNMT3A 
activity may lead to epigenetic changes that alter the 
normal transcription of tumor suppressor genes needed 
to dampen Shp2 signaling. Future work doing a genome-
wide transcriptional analysis would help to elucidate the 




Mice with a conditional mutant Shp2 allele, LSL-
Shp2D61Y/+, have been previously described [9]. Mice with a 
conditional knockout Dnmt3a allele have been previously 
described [13]. Expression of the D61Y mutation, the 
Dnmt3a mutation, and Mx1-cre were confirmed by 
genotyping. Three intraperitoneal injections of 300ug 
polyI:polyC were administered concurrently to mice of 
each cohort. Mice were housed and bred in accordance 
with the Institutional Animal Care and Use Committee of 
the Indiana University School of Medicine.
Flow cytometry
Cell suspensions were incubated for 5 minutes 
with 10% rat serum (MP Biomedicals) and 0.2% BSA 
Figure 5: Dnmt3a+/−;D61Y mice have anemia with compensatory erythropoiesis in spleen. (A) Average peripheral blood 
red blood cell (RBC) count in mice immediately prior to euthanasia; n = 8 for WT, n = 7 for Dnmt3a+/−, n = 5 for D61Y, n = 5 for 
Dnmt3a+/−;D61Y, *p = 0.0005 comparing Dnmt3a+/−;D61Y to WT. (B) Average peripheral blood hemoglobin values in mice immediately 
prior to euthanasia; n = 8 for WT, n = 6 for Dnmt3a+/−, n = 5 for D61Y, n = 5 for Dnmt3a+/−;D61Y, *p = 0.0002 comparing Dnmt3a+/−;D61Y 
to WT, *p = 0.0016 comparing Dnmt3a+/−;D61Y to Dnmt3a+/−. (C) Average peripheral blood hematocrit values in mice immediately prior 
to euthanasia; n = 8 for WT, n = 7 for Dnmt3a+/−, n = 5 for D61Y, n = 5 for Dnmt3a+/−;D61Y, *p = 0.001 comparing Dnmt3a+/−;D61Y to WT, 
statistical analyses performed by unpaired, two-tailed, Student’s t-test. (D) Average percentage of erythroid progenitors (CD36+CD71+) 
in spleen gated on live events, with (E) representative flow diagrams; n = 6 for WT, n = 4 for Dnmt3a+/−, n = 3 for D61Y, n = 3 for 
Dnmt3a+/−;D61Y; *p = 0.0177 comparing Dnmt3a+/−;D61Y to WT, statistical analyses performed by unpaired, two-tailed, Student’s t-test.
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(Roche) in PBS, then stained for 30 minutes at 4°C with 
biotinylated lineage markers (Mac1, Gr1, CD4, CD8, 
B220, Ter119, IL7Rα, CD19, and CD3 with streptavidin 
PerCPcy5.5 as secondary), anti-Sca1-PE, anti-cKit-APC, 
anti-CD34-FITC, anti-CD16/32-PEcy7, anti-Gr1-FITC, 
anti-Mac1-APC, biotinylated anti-CD4 and anti-CD8 
(with streptavidin APC as secondary), anti-B220-PE, 
anti-CD71-PE, and/or anti-CD36-APC (eBioscience 
and BD Biosciences). The analyzer used for flow 
cytometry was the BD LSR II and data was analyzed 
using CellQuest.
Complete blood counts
Peripheral blood was collected from the saphenous 
vein of mice and complete blood counts were measured 
using a Hemavet 950 (Drew Scientific Group).
Statistical calculations
GraphPad was used to perform the unpaired, two-
tailed, Student’s t-tests.
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